U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C30H53N3O6
Molecular Weight 551.7595
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALISKIREN

SMILES

CC(C)[C@@]([H])(Cc1ccc(c(c1)OCCCOC)OC)C[C@@]([H])([C@]([H])(C[C@@]([H])(C(C)C)C(=NCC(C)(C)C(=N)O)O)O)N

InChI

InChIKey=UXOWGYHJODZGMF-QORCZRPOSA-N
InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1

HIDE SMILES / InChI

Molecular Formula C30H53N3O6
Molecular Weight 551.7595
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Aliskiren – the only direct renin inhibitor which is clinically used as an antihypertensive drug. Aliskiren is the first of a new class of antihypertensive agents. Aliskiren is a new renin inhibitor of a novel structural class that has recently been shown to be efficacious in hypertensive patients after once-daily oral dosing. In short-term studies, it was effective in lowering blood pressure either alone or in combination with valsartan and hydrochlorothiazide, and had a low incidence of serious adverse effects. It was approved by the Food and Drug Administration in 2007 for the use as a monotherapy or in combination with other antihypertensives. Aliskiren is marketed under the trade name Tekturna. Aliskiren effectively reduces functional plasma renin activity by binding to renin with high affinity, preventing it from converting angiotensinogen to angiotensin I. The inhibition of renin by aliskiren is associated with a reduction in circulating levels of angiotensin I and II, with a resultant increase in plasma renin concentration and inhibit activation of mitogen-activated protein kinases ERK1 (p44) and ERK2 (p42).

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TEKTURNA

Approved Use

Amturnide is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine and hydrochlorothiazide (HCTZ). There are no controlled trials demonstrating risk reduction with Amturnide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality have also been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed combination drug is not indicated for initial therapy of hypertension. Amturnide is a combination of aliskiren, a renin inhibitor, amlodipine besylate, a dihydropyridine calcium channel blocker, and hydrochlorothiazide (HCTZ), a thiazide diuretic. Amturnide is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions: Not indicated for initial therapy. (1)

Launch Date

1.17305285E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
290.2 ng/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ALISKIREN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
102 ng/mL
300 mg 1 times / day steady, oral
dose: 300 mg
route of administration: oral
experiment type: steady
co-administered:
ALISKIREN plasma
Homo sapiens
population: unhealthy
age:
sex:
food status: Fed
108 ng/mL
300 mg 1 times / day steady, oral
dose: 300 mg
route of administration: oral
experiment type: steady
co-administered:
ALISKIREN plasma
Homo sapiens
population: unhealthy
age:
sex:
food status: Fed
252 ng/mL
300 mg 1 times / day steady, oral
dose: 300 mg
route of administration: oral
experiment type: steady
co-administered:
ALISKIREN plasma
Homo sapiens
population: unhealthy
age:
sex:
food status: Fasted
273 ng/mL
300 mg 1 times / day steady, oral
dose: 300 mg
route of administration: oral
experiment type: steady
co-administered:
ALISKIREN plasma
Homo sapiens
population: unhealthy
age:
sex:
food status: Fasted
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1399 ng × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ALISKIREN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
1100 ng*h/mL
300 mg 1 times / day steady, oral
dose: 300 mg
route of administration: oral
experiment type: steady
co-administered:
ALISKIREN plasma
Homo sapiens
population: unhealthy
age:
sex:
food status: Fed
1540 ng*h/mL
300 mg 1 times / day steady, oral
dose: 300 mg
route of administration: oral
experiment type: steady
co-administered:
ALISKIREN plasma
Homo sapiens
population: unhealthy
age:
sex:
food status: Fasted
1580 ng*h/mL
300 mg 1 times / day steady, oral
dose: 300 mg
route of administration: oral
experiment type: steady
co-administered:
ALISKIREN plasma
Homo sapiens
population: unhealthy
age:
sex:
food status: Fasted
872 ng*h/mL
300 mg 1 times / day steady, oral
dose: 300 mg
route of administration: oral
experiment type: steady
co-administered:
ALISKIREN plasma
Homo sapiens
population: unhealthy
age:
sex:
food status: Fed
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
41 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ALISKIREN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
600 mg single, oral
Highest studied dose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 18 - 45
n = 8
Health Status: healthy
Age Group: 18 - 45
Sex: M+F
Population Size: 8
Sources:
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources: Page: p.1161
unhealthy, 53
n = 166
Health Status: unhealthy
Condition: Hypertension
Age Group: 53
Sex: M+F
Population Size: 166
Sources: Page: p.1161
Disc. AE: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (0.6%)
Sources: Page: p.1161
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
Disc. AE: Disorder fetal, Angioedema...
AEs leading to
discontinuation/dose reduction:
Disorder fetal
Angioedema
Angioedema
Hypotension
Impaired renal function
Hyperkalemia
Sources: Page: p.1
150 mg 1 times / day steady, oral
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: Kidney Transplant
Population Size: 7
Sources:
Other AEs: GI bleed, Knee hemarthrosis...
Other AEs:
GI bleed (serious, 1 patient)
Knee hemarthrosis (serious, 1 patient)
Diarrhea (below serious, 5 patients)
Lower extremities weakness of (below serious, 1 patient)
Sources:
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Other AEs: Cellulitis, Pneumonia...
Other AEs:
Cellulitis (serious, 1 patient)
Pneumonia (serious, 1 patient)
Diabetic foot (serious, 1 patient)
Choroidal neovascularisation (below serious, 1 patient)
Foreign body sensation in eyes (below serious, 1 patient)
Asteroid hyalosis (below serious, 1 patient)
Retinal neovascularisation (below serious, 1 patient)
Vision blurred (below serious, 1 patient)
Vitreous detachment (below serious, 1 patient)
Diarrhoea (below serious, 1 patient)
Flatulence (below serious, 1 patient)
Fatigue (below serious, 1 patient)
Fungal skin infection (below serious, 1 patient)
Respiratory tract infection (below serious, 1 patient)
Sinusitis (below serious, 1 patient)
Tooth fracture (below serious, 1 patient)
Hypoglycaemia (below serious, 1 patient)
Arthritis (below serious, 1 patient)
Muscle spasms (below serious, 1 patient)
Myalgia (below serious, 1 patient)
Pain in extremity (below serious, 1 patient)
Pain in jaw (below serious, 1 patient)
Basal cell carcinoma (below serious, 2 patients)
Paraesthesia (below serious, 1 patient)
Epistaxis (below serious, 1 patient)
Hypotension (below serious, 2 patients)
Sources:
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Other AEs: Anaemia, Haemorrhagic disorder...
Other AEs:
Anaemia (serious, 6 patients)
Haemorrhagic disorder (serious, 1 patient)
Hilar lymphadenopathy (serious, 1 patient)
Lymphadenopathy (serious, 1 patient)
Splenic infarction (serious, 1 patient)
Angina unstable (serious, 7 patients)
Aortic valve incompetence (serious, 1 patient)
Arteriospasm coronary (serious, 1 patient)
Atrial flutter (serious, 3 patients)
Atrioventricular block complete (serious, 2 patients)
Cardio-respiratory arrest (serious, 7 patients)
Cardiogenic shock (serious, 7 patients)
Cardiomyopathy (serious, 1 patient)
Cardiopulmonary failure (serious, 2 patients)
Coronary artery disease (serious, 4 patients)
Left ventricular dysfunction (serious, 1 patient)
Low cardiac output syndrome (serious, 1 patient)
Fibrosis myocardial (serious, 1 patient)
Tachyarrhythmia (serious, 1 patient)
Tachycardia (serious, 3 patients)
Ventricular extrasystoles (serious, 1 patient)
Ventricular tachycardia (serious, 10 patients)
Vertigo (serious, 4 patients)
Cataract (serious, 3 patients)
Retinal detachment (serious, 1 patient)
Constipation (serious, 2 patients)
Duodenal ulcer haemorrhage (serious, 1 patient)
Enterocolitis (serious, 1 patient)
Gastritis (serious, 1 patient)
Hiatus hernia (serious, 1 patient)
Intestinal obstruction (serious, 1 patient)
Intestinal polyp (serious, 1 patient)
Nausea (serious, 8 patients)
Small intestinal obstruction (serious, 1 patient)
Umbilical hernia, obstructive (serious, 1 patient)
Upper gastrointestinal haemorrhage (serious, 1 patient)
Vomiting (serious, 5 patients)
Chest discomfort (serious, 1 patient)
Chest pain (serious, 6 patients)
Device lead issue (serious, 1 patient)
Drug intolerance (serious, 1 patient)
Necrosis (serious, 1 patient)
Non-cardiac chest pain (serious, 7 patients)
Soft tissue inflammation (serious, 1 patient)
Sudden death (serious, 9 patients)
Cholecystitis (serious, 2 patients)
Hepatic cirrhosis (serious, 1 patient)
Hepatic cyst (serious, 1 patient)
Hepatorenal syndrome (serious, 1 patient)
Heart transplant rejection (serious, 1 patient)
Anal abscess (serious, 1 patient)
Appendicitis (serious, 2 patients)
Bronchitis bacterial (serious, 1 patient)
Erysipelas (serious, 2 patients)
Gastrointestinal viral infection (serious, 1 patient)
Hepatitis B (serious, 1 patient)
Liver abscess (serious, 1 patient)
Infection localised (serious, 1 patient)
Lower respiratory tract infection (serious, 3 patients)
Orchitis (serious, 1 patient)
Osteomyelitis acute (serious, 1 patient)
Paronychia (serious, 1 patient)
Pseudomembranous colitis (serious, 2 patients)
Respiratory tract infection (serious, 3 patients)
Sepsis (serious, 8 patients)
Viral infection (serious, 1 patient)
Wound infection pseudomonas (serious, 1 patient)
Accidental overdose (serious, 1 patient)
Ankle fracture (serious, 1 patient)
Contusion (serious, 1 patient)
Dermatitis artefacta (serious, 1 patient)
Electric shock (serious, 1 patient)
Extradural haematoma (serious, 1 patient)
Femoral neck fracture (serious, 1 patient)
Femur fracture (serious, 4 patients)
Head injury (serious, 1 patient)
Humerus fracture (serious, 2 patients)
Laceration (serious, 1 patient)
Post procedural haematoma (serious, 1 patient)
Procedural haemorrhage (serious, 1 patient)
Pubis fracture (serious, 1 patient)
Spinal compression fracture (serious, 1 patient)
Splenic rupture (serious, 1 patient)
Subdural haematoma (serious, 2 patients)
Thermal burn (serious, 1 patient)
Toxicity to various agents (serious, 2 patients)
Blood creatinine increased (serious, 3 patients)
Haemoglobin decreased (serious, 1 patient)
International normalised ratio increased (serious, 2 patients)
Renal function test abnormal (serious, 1 patient)
Decreased appetite (serious, 1 patient)
Diabetic ketoacidosis (serious, 1 patient)
Failure to thrive (serious, 1 patient)
Fluid intake reduced (serious, 1 patient)
Hypoglycaemia (serious, 7 patients)
Arthralgia (serious, 1 patient)
Arthritis (serious, 1 patient)
Bursitis (serious, 1 patient)
Costochondritis (serious, 1 patient)
Joint effusion (serious, 1 patient)
Muscular weakness (serious, 1 patient)
Pain in extremity (serious, 2 patients)
Bladder neoplasm (serious, 1 patient)
Colon cancer (serious, 2 patients)
Colorectal cancer (serious, 1 patient)
Hepatic neoplasm (serious, 1 patient)
Hepatobiliary neoplasm (serious, 1 patient)
Adenocarcinoma lung (serious, 1 patient)
Lung neoplasm malignant (serious, 1 patient)
Lung squamous cell carcinoma stage unspecified (serious, 1 patient)
Multiple myeloma (serious, 1 patient)
Prostate cancer metastatic (serious, 1 patient)
Uterine leiomyoma (serious, 1 patient)
Anterior spinal artery syndrome (serious, 1 patient)
Burning sensation (serious, 1 patient)
Cerebral haematoma (serious, 1 patient)
Coma (serious, 1 patient)
Diabetic neuropathy (serious, 1 patient)
Dizziness (serious, 4 patients)
Dysarthria (serious, 1 patient)
Embolic stroke (serious, 2 patients)
Epilepsy (serious, 2 patients)
Haemorrhagic stroke (serious, 1 patient)
Intracranial haematoma (serious, 1 patient)
Loss of consciousness (serious, 1 patient)
Metabolic encephalopathy (serious, 1 patient)
Myasthenia gravis (serious, 1 patient)
Myasthenia gravis crisis (serious, 1 patient)
Neuropathy peripheral (serious, 1 patient)
Somnolence (serious, 2 patients)
Trigeminal neuralgia (serious, 1 patient)
Unresponsive to stimuli (serious, 1 patient)
Uraemic encephalopathy (serious, 1 patient)
Abnormal behaviour (serious, 1 patient)
Alcohol abuse (serious, 1 patient)
Anxiety (serious, 1 patient)
Confusional state (serious, 2 patients)
Depression suicidal (serious, 1 patient)
Screaming (serious, 1 patient)
Bladder tamponade (serious, 1 patient)
Haematuria (serious, 1 patient)
Nephropathy (serious, 1 patient)
Polyuria (serious, 1 patient)
Renal artery stenosis (serious, 1 patient)
Renal failure acute (serious, 20 patients)
Renal impairment (serious, 5 patients)
Benign prostatic hyperplasia (serious, 2 patients)
Menorrhagia (serious, 1 patient)
Acute pulmonary oedema (serious, 7 patients)
Acute respiratory distress syndrome (serious, 1 patient)
Acute respiratory failure (serious, 2 patients)
Asthma (serious, 1 patient)
Atelectasis (serious, 1 patient)
Bronchiectasis (serious, 1 patient)
Chronic obstructive pulmonary disease (serious, 13 patients)
Dyspnoea (serious, 20 patients)
Pneumonitis (serious, 1 patient)
Pneumothorax (serious, 1 patient)
Productive cough (serious, 1 patient)
Pulmonary artery thrombosis (serious, 1 patient)
Respiratory failure (serious, 6 patients)
Wheezing (serious, 1 patient)
Hyperhidrosis (serious, 2 patients)
Skin ulcer (serious, 1 patient)
Skin ulcer haemorrhage (serious, 1 patient)
Extremity necrosis (serious, 1 patient)
Hypotension (serious, 24 patients)
Peripheral arterial occlusive disease (serious, 4 patients)
Peripheral ischaemia (serious, 1 patient)
Disorder peripheral vascular (serious, 2 patients)
Phlebitis (serious, 1 patient)
Diarrhoea (below serious, 49 patients)
Hyperkalaemia (below serious, 155 patients)
Renal impairment (below serious, 47 patients)
Cough (below serious, 59 patients)
Hypotension (below serious, 117 patients)
Sources:
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 25
Health Status: unhealthy
Condition: Heart Failure and a Normal Ejection Fraction
Population Size: 25
Sources:
Other AEs: Thrush NOS...
Other AEs:
Thrush NOS (below serious, 1 patient)
Sources:
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 34
Health Status: unhealthy
Condition: Atherosclerosis
Population Size: 34
Sources:
Other AEs: Hyperkalemia...
Other AEs:
Hyperkalemia (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Diarrhea 0.6%
Disc. AE
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources: Page: p.1161
unhealthy, 53
n = 166
Health Status: unhealthy
Condition: Hypertension
Age Group: 53
Sex: M+F
Population Size: 166
Sources: Page: p.1161
Angioedema Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
Angioedema Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
Disorder fetal Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
Hyperkalemia Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
Hypotension Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
Impaired renal function Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
Lower extremities weakness of below serious, 1 patient
150 mg 1 times / day steady, oral
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: Kidney Transplant
Population Size: 7
Sources:
Diarrhea below serious, 5 patients
150 mg 1 times / day steady, oral
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: Kidney Transplant
Population Size: 7
Sources:
GI bleed serious, 1 patient
150 mg 1 times / day steady, oral
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: Kidney Transplant
Population Size: 7
Sources:
Knee hemarthrosis serious, 1 patient
150 mg 1 times / day steady, oral
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: Kidney Transplant
Population Size: 7
Sources:
Arthritis below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Asteroid hyalosis below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Choroidal neovascularisation below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Diarrhoea below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Epistaxis below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Fatigue below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Flatulence below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Foreign body sensation in eyes below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Fungal skin infection below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Hypoglycaemia below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Muscle spasms below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Myalgia below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Pain in extremity below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Pain in jaw below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Paraesthesia below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Respiratory tract infection below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Retinal neovascularisation below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Sinusitis below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Tooth fracture below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Vision blurred below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Vitreous detachment below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Basal cell carcinoma below serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Hypotension below serious, 2 patients
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Cellulitis serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Diabetic foot serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Pneumonia serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: diabetic macular edema
Population Size: 20
Sources:
Hypotension below serious, 117 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Hyperkalaemia below serious, 155 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Renal impairment below serious, 47 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Diarrhoea below serious, 49 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Cough below serious, 59 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Abnormal behaviour serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Accidental overdose serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Acute respiratory distress syndrome serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Adenocarcinoma lung serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Alcohol abuse serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Anal abscess serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Ankle fracture serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Anterior spinal artery syndrome serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Anxiety serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Aortic valve incompetence serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Arteriospasm coronary serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Arthralgia serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Arthritis serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Asthma serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Atelectasis serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Bladder neoplasm serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Bladder tamponade serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Bronchiectasis serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Bronchitis bacterial serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Burning sensation serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Bursitis serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Cardiomyopathy serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Cerebral haematoma serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Chest discomfort serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Colorectal cancer serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Coma serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Contusion serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Costochondritis serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Decreased appetite serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Depression suicidal serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Dermatitis artefacta serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Device lead issue serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Diabetic ketoacidosis serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Diabetic neuropathy serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Drug intolerance serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Duodenal ulcer haemorrhage serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Dysarthria serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Electric shock serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Enterocolitis serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Extradural haematoma serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Extremity necrosis serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Failure to thrive serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Femoral neck fracture serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Fibrosis myocardial serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Fluid intake reduced serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Gastritis serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Gastrointestinal viral infection serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Haematuria serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Haemoglobin decreased serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Haemorrhagic disorder serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Haemorrhagic stroke serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Head injury serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Heart transplant rejection serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Hepatic cirrhosis serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Hepatic cyst serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Hepatic neoplasm serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Hepatitis B serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Hepatobiliary neoplasm serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Hepatorenal syndrome serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Hiatus hernia serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Hilar lymphadenopathy serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Infection localised serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Intestinal obstruction serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Intestinal polyp serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Intracranial haematoma serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Joint effusion serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Laceration serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Left ventricular dysfunction serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Liver abscess serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Loss of consciousness serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Low cardiac output syndrome serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Lung neoplasm malignant serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Lung squamous cell carcinoma stage unspecified serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Lymphadenopathy serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Menorrhagia serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Metabolic encephalopathy serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Multiple myeloma serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Muscular weakness serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Myasthenia gravis crisis serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Myasthenia gravis serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Necrosis serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Nephropathy serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Neuropathy peripheral serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Orchitis serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Osteomyelitis acute serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Paronychia serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Peripheral ischaemia serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Phlebitis serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Pneumonitis serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Pneumothorax serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Polyuria serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Post procedural haematoma serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Procedural haemorrhage serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Productive cough serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Prostate cancer metastatic serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Pubis fracture serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Pulmonary artery thrombosis serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Renal artery stenosis serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Renal function test abnormal serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Retinal detachment serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Screaming serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Skin ulcer haemorrhage serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Skin ulcer serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Small intestinal obstruction serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Soft tissue inflammation serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Spinal compression fracture serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Splenic infarction serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Splenic rupture serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Tachyarrhythmia serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Thermal burn serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Trigeminal neuralgia serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Umbilical hernia, obstructive serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Unresponsive to stimuli serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Upper gastrointestinal haemorrhage serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Uraemic encephalopathy serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Uterine leiomyoma serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Ventricular extrasystoles serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Viral infection serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Wheezing serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Wound infection pseudomonas serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Ventricular tachycardia serious, 10 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Chronic obstructive pulmonary disease serious, 13 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Acute respiratory failure serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Appendicitis serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Atrioventricular block complete serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Benign prostatic hyperplasia serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Cardiopulmonary failure serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Cholecystitis serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Colon cancer serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Confusional state serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Constipation serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Disorder peripheral vascular serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Embolic stroke serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Epilepsy serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Erysipelas serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Humerus fracture serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Hyperhidrosis serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
International normalised ratio increased serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Pain in extremity serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Pseudomembranous colitis serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Somnolence serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Subdural haematoma serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Toxicity to various agents serious, 2 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Dyspnoea serious, 20 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Renal failure acute serious, 20 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Hypotension serious, 24 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Atrial flutter serious, 3 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Blood creatinine increased serious, 3 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Cataract serious, 3 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Lower respiratory tract infection serious, 3 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Respiratory tract infection serious, 3 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Tachycardia serious, 3 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Coronary artery disease serious, 4 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Dizziness serious, 4 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Femur fracture serious, 4 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Peripheral arterial occlusive disease serious, 4 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Vertigo serious, 4 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Renal impairment serious, 5 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Vomiting serious, 5 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Anaemia serious, 6 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Chest pain serious, 6 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Respiratory failure serious, 6 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Acute pulmonary oedema serious, 7 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Angina unstable serious, 7 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Cardio-respiratory arrest serious, 7 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Cardiogenic shock serious, 7 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Hypoglycaemia serious, 7 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Non-cardiac chest pain serious, 7 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Nausea serious, 8 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Sepsis serious, 8 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Sudden death serious, 9 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 808
Health Status: unhealthy
Condition: acute decompensated Heart Failure
Population Size: 808
Sources:
Thrush NOS below serious, 1 patient
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 25
Health Status: unhealthy
Condition: Heart Failure and a Normal Ejection Fraction
Population Size: 25
Sources:
Hyperkalemia below serious, 1 patient
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 34
Health Status: unhealthy
Condition: Atherosclerosis
Population Size: 34
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
inconclusive
major
yes (co-administration study)
Comment: itraconazole increased Cmax by 5-fold and AUC by 6-fold; ketaconazole increased Cmax a nd AUC by 2-fold; cyclosporine increased Cmax by 5-fold and AUC by 3-fold
Page: 30.0
minor
no
no
no
no
yes
yes (co-administration study)
Comment: from clinical pharmacology review pdf 4: ketaconazole increased Cmax by 81% and AUC by 76%; from product label: itraconazole increased Cmax by 5-fold and AUC by 6-fold; cyclosporine increased Cmax by 5-fold and AUC by 3-fold
Page: 31.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Aliskiren (Speedel).
2002 Oct
Gateways to Clinical Trials.
2002 Sep
Therapeutic potential of renin inhibitors in the management of cardiovascular disorders.
2003
Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.
2003 Dec
Structure-based design of aliskiren, a novel orally effective renin inhibitor.
2003 Sep 5
Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
2004 Dec
Gateways to clinical trials.
2004 Jul-Aug
Gateways to clinical trials.
2004 May
Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects.
2004 Oct
Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats.
2005 Feb
Renin inhibition: new potential for an old therapeutic target.
2005 Sep
Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus.
2006
Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension.
2006 Dec
Gateways to clinical trials.
2006 Jun
Direct renin inhibition with aliskiren in hypertension and target organ damage.
2006 Mar
Renin inhibitors: An important advance in hypertension treatment?
2006 Nov
Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II.
2006 Oct
Oral renin inhibitors.
2006 Oct 21
Aliskiren: a review of its use in the management of hypertension.
2007
Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy.
2007
The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension.
2007
Expanding the opportunities for blocking the renin-angiotensin system: introduction to a special supplement.
2007
Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
2007 Apr
Antihypertensive therapies.
2007 Aug
Renin inhibition: a new modality for hypertension management.
2007 Aug
Direct renin inhibitors: a new approach to antihypertensive drug treatment.
2007 Aug
An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
2007 Aug 2
Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
2007 Feb
[The best of clinical pharmacology in 2006].
2007 Jan
[The best of hypertension in 2006].
2007 Jan
Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
2007 Jan
Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
2007 Jan
Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.
2007 Jul 21
Low-dose renin inhibitor and low-dose AT(1)-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes.
2007 Jun
Gateways to clinical trials.
2007 Mar
Aliskiren for renin inhibition: a new class of antihypertensives.
2007 Mar
Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension.
2007 Mar 20
Identification of hot spots within druggable binding regions by computational solvent mapping of proteins.
2007 Mar 22
A new way to control blood pressure. Inactivating renin, which is made by the kidneys, may open the door to better blood pressure.
2007 May
What new drugs can nephrologists look forward to in the next year or two?
2007 May
Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats.
2007 Nov
Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets.
2007 Oct 4
Aliskiren, the future of renin-angiotensin system blockade?
2007 Sep
The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren.
2007 Sep
Inhibition of renin: an updated review of the development of renin inhibitors.
2007 Sep
Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
2007 Sep
Renin excess after renin inhibition: malefactor or innocent bystander?
2007 Sep
Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
2007 Sep-Oct
Patents

Sample Use Guides

Starting dose: 150 mg once daily with a routine pattern with regard to meals. If blood pressure remains uncontrolled titrate up to 300 mg daily (2.1, 2.3) Majority of effect of given dose attained in 2 weeks
Route of Administration: Oral
Aliskiren (0.1 or 10 uM) dose-dependently improved functions and increased both VEGF and stromal cell-derived factor-1α (SDF-1α) expression of EPCs from patients with T2DM or EPCs from healthy volunteers and treated with high glucose.
Substance Class Chemical
Created
by admin
on Sat Jun 26 02:01:47 UTC 2021
Edited
by admin
on Sat Jun 26 02:01:47 UTC 2021
Record UNII
502FWN4Q32
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALISKIREN
EMA EPAR   HSDB   INN   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
ALISKIREN [INN]
Common Name English
ALISKIREN [USAN]
Common Name English
ALISKIREN [EMA EPAR]
Common Name English
SPP-100
Code English
SPP100
Code English
ALISKIREN [WHO-DD]
Common Name English
ALISKIREN [MI]
Common Name English
ALISKIREN [HSDB]
Common Name English
ALISKIREN [VANDF]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175900
Created by admin on Sat Jun 26 02:01:48 UTC 2021 , Edited by admin on Sat Jun 26 02:01:48 UTC 2021
NCI_THESAURUS C270
Created by admin on Sat Jun 26 02:01:48 UTC 2021 , Edited by admin on Sat Jun 26 02:01:48 UTC 2021
WHO-VATC QC09XA02
Created by admin on Sat Jun 26 02:01:48 UTC 2021 , Edited by admin on Sat Jun 26 02:01:48 UTC 2021
WHO-VATC QC09XA53
Created by admin on Sat Jun 26 02:01:48 UTC 2021 , Edited by admin on Sat Jun 26 02:01:48 UTC 2021
WHO-ATC C09XA53
Created by admin on Sat Jun 26 02:01:47 UTC 2021 , Edited by admin on Sat Jun 26 02:01:47 UTC 2021
WHO-ATC C09XA54
Created by admin on Sat Jun 26 02:01:47 UTC 2021 , Edited by admin on Sat Jun 26 02:01:47 UTC 2021
WHO-ATC C09XA02
Created by admin on Sat Jun 26 02:01:47 UTC 2021 , Edited by admin on Sat Jun 26 02:01:47 UTC 2021
WHO-ATC C09XA52
Created by admin on Sat Jun 26 02:01:47 UTC 2021 , Edited by admin on Sat Jun 26 02:01:47 UTC 2021
NDF-RT N0000175899
Created by admin on Sat Jun 26 02:01:48 UTC 2021 , Edited by admin on Sat Jun 26 02:01:48 UTC 2021
WHO-ATC C09DX02
Created by admin on Sat Jun 26 02:01:47 UTC 2021 , Edited by admin on Sat Jun 26 02:01:47 UTC 2021
WHO-VATC QC09XA52
Created by admin on Sat Jun 26 02:01:48 UTC 2021 , Edited by admin on Sat Jun 26 02:01:48 UTC 2021
LIVERTOX 25
Created by admin on Sat Jun 26 02:01:48 UTC 2021 , Edited by admin on Sat Jun 26 02:01:48 UTC 2021
WHO-VATC QC09DX02
Created by admin on Sat Jun 26 02:01:48 UTC 2021 , Edited by admin on Sat Jun 26 02:01:48 UTC 2021
Code System Code Type Description
WIKIPEDIA
ALISKIREN
Created by admin on Sat Jun 26 02:01:48 UTC 2021 , Edited by admin on Sat Jun 26 02:01:48 UTC 2021
PRIMARY
HSDB
7843
Created by admin on Sat Jun 26 02:01:47 UTC 2021 , Edited by admin on Sat Jun 26 02:01:47 UTC 2021
PRIMARY
MERCK INDEX
M1509
Created by admin on Sat Jun 26 02:01:48 UTC 2021 , Edited by admin on Sat Jun 26 02:01:48 UTC 2021
PRIMARY Merck Index
CAS
173334-57-1
Created by admin on Sat Jun 26 02:01:47 UTC 2021 , Edited by admin on Sat Jun 26 02:01:47 UTC 2021
PRIMARY
FDA UNII
502FWN4Q32
Created by admin on Sat Jun 26 02:01:47 UTC 2021 , Edited by admin on Sat Jun 26 02:01:47 UTC 2021
PRIMARY
ChEMBL
CHEMBL1639
Created by admin on Sat Jun 26 02:01:47 UTC 2021 , Edited by admin on Sat Jun 26 02:01:47 UTC 2021
PRIMARY
RXCUI
325646
Created by admin on Sat Jun 26 02:01:48 UTC 2021 , Edited by admin on Sat Jun 26 02:01:48 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C65222
Created by admin on Sat Jun 26 02:01:48 UTC 2021 , Edited by admin on Sat Jun 26 02:01:48 UTC 2021
PRIMARY
DRUG CENTRAL
119
Created by admin on Sat Jun 26 02:01:47 UTC 2021 , Edited by admin on Sat Jun 26 02:01:47 UTC 2021
PRIMARY
MESH
C446481
Created by admin on Sat Jun 26 02:01:48 UTC 2021 , Edited by admin on Sat Jun 26 02:01:48 UTC 2021
PRIMARY
INN
7992
Created by admin on Sat Jun 26 02:01:47 UTC 2021 , Edited by admin on Sat Jun 26 02:01:47 UTC 2021
PRIMARY
IUPHAR
4812
Created by admin on Sat Jun 26 02:01:48 UTC 2021 , Edited by admin on Sat Jun 26 02:01:48 UTC 2021
PRIMARY
PUBCHEM
5493444
Created by admin on Sat Jun 26 02:01:48 UTC 2021 , Edited by admin on Sat Jun 26 02:01:48 UTC 2021
PRIMARY
EVMPD
SUB21380
Created by admin on Sat Jun 26 02:01:47 UTC 2021 , Edited by admin on Sat Jun 26 02:01:47 UTC 2021
PRIMARY
DRUG BANK
DB09026
Created by admin on Sat Jun 26 02:01:47 UTC 2021 , Edited by admin on Sat Jun 26 02:01:47 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
TARGET -> INHIBITOR
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
EXCRETED UNCHANGED
AMOUNT EXCRETED
FECAL
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
ORAL BIOAVAILABILITY PHARMACOKINETIC
blood-to-plasma ratio PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC